Japan’s Drug Regulation Framework: Aiming for Better Health or Bigger Profits?

Document Type : Letter to Editor


1 Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan

2 Medical Governance Research Institute, Tokyo, Japan

3 Faculty of Medicine, Comenius University, Bratislava, Slovakia

4 Department of Gastroenterology, Sendai Kousei Hospital, Miyagi, Japan

5 Kitasato University, Tokyo, Japan


Dear Editor,

The advent of novel therapeutics has caused the rising cost of drugs to become of increasing global concern. Countries with universal healthcare systems, such as Japan and the United Kingdom, face a seemingly unsolvable conundrum of how to sustain their exorbitantly expensive public healthcare systems in a cost-effective manner... (Read more...)

Cyranoski D. The potent effects of Japan's stem-cell policies. Nature 2019;573:482-485. doi:10.1038/d41586-019-02847-3
Japan should put the brakes on stem-cell sales. Nature 2019;565:535-536. doi:10.1038/d41586-019-00332-5
Sipp D, Sleeboom-Faulkner M. Downgrading of regulation in regenerative medicine. Science 2019;365(6454):644. doi:10.1126/science.aax6184
Nature editorial. A stem-cell race that no one wins. Nature 2019;573(7775):463. doi:10.1038/d41586-019-02844-6
Pharmaceutical and Medical Devices Agency. Regenerative medicine products (attachments). 2020; https://www.pmda.go.jp/safety/info-services/ctp/0001.html?fbclid=IwAR1UiPIJ4kCTkTjUV_sC5tPYpw49oECLxPiQflGxoPr2nFUYqVvw7SmLh9s.  Updated January 4, 2019. Accessed 7 April, 2020.
The Japan Pharmaceutical Manufacturers Association. Information on Japanese Regulatory Affairs; 2019; http://www.jpma.or.jp/english/parj/pdf/2020.pdf.  Accessed 7 April, 2020.
Tanimoto T. A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan. Drug Design, Development and Therapy 2015;9:1877-1888. doi:10.2147/DDDT.S62636
Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2019;20(7):984-997. doi:10.1016/S1470-2045(19)30150-0
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med.  2018;379(22):2108-2121. doi:10.1056/NEJMoa1809615